Literature DB >> 26592448

Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.

S Diersch1, M Wirth1, C Schneeweis1, S Jörs1, F Geisler1, J T Siveke1,2, R Rad1, R M Schmid1, D Saur1, A K Rustgi3,4,5,6, M Reichert1,3,6, G Schneider1.   

Abstract

Epidermal growth factor receptor (EGFR) signaling has a critical role in oncogenic Kras-driven pancreatic carcinogenesis. However, the downstream targets of this signaling network are largely unknown. We developed a novel model system utilizing murine primary pancreatic ductal epithelial cells (PDECs), genetically engineered to allow time-specific expression of oncogenic Kras(G12D) from the endogenous promoter. We show that primary PDECs are susceptible to Kras(G12D)-driven transformation and form pancreatic ductal adenocarcinomas in vivo after Cdkn2a inactivation. In addition, we demonstrate that activation of Kras(G12D) induces an EGFR signaling loop to drive proliferation. Interestingly, pharmacological inhibition of EGFR fails to decrease Kras(G12D)-activated ERK or PI3K signaling. Instead our data provide novel evidence that EGFR signaling is needed to activate the oncogenic and pro-proliferative transcription factor c-MYC. EGFR and c-MYC have been shown to be essential for pancreatic carcinogenesis. Importantly, our data link both pathways and thereby explain the crucial role of EGFR for Kras(G12D)-driven carcinogenesis in the pancreas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26592448      PMCID: PMC4877299          DOI: 10.1038/onc.2015.437

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

1.  p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells.

Authors:  Andreia V Pinho; Ilse Rooman; Francisco X Real
Journal:  Cell Cycle       Date:  2011-04-15       Impact factor: 4.534

2.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

3.  Pancreatic exocrine duct cells give rise to insulin-producing beta cells during embryogenesis but not after birth.

Authors:  Myriam Solar; Carina Cardalda; Isabelle Houbracken; Mercè Martín; Miguel Angel Maestro; Nele De Medts; Xiaobo Xu; Vanessa Grau; Harry Heimberg; Luc Bouwens; Jorge Ferrer
Journal:  Dev Cell       Date:  2009-12       Impact factor: 12.270

4.  Analysis of C-MYC function in normal cells via conditional gene-targeted mutation.

Authors:  I M de Alboran; R C O'Hagan; F Gärtner; B Malynn; L Davidson; R Rickert; K Rajewsky; R A DePinho; F W Alt
Journal:  Immunity       Date:  2001-01       Impact factor: 31.745

5.  Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Authors:  Pawel K Mazur; Alexander Herner; Stephano S Mello; Matthias Wirth; Simone Hausmann; Francisco J Sánchez-Rivera; Shane M Lofgren; Timo Kuschma; Stephan A Hahn; Deepak Vangala; Marija Trajkovic-Arsic; Aayush Gupta; Irina Heid; Peter B Noël; Rickmer Braren; Mert Erkan; Jörg Kleeff; Bence Sipos; Leanne C Sayles; Mathias Heikenwalder; Elisabeth Heßmann; Volker Ellenrieder; Irene Esposito; Tyler Jacks; James E Bradner; Purvesh Khatri; E Alejandro Sweet-Cordero; Laura D Attardi; Roland M Schmid; Guenter Schneider; Julien Sage; Jens T Siveke
Journal:  Nat Med       Date:  2015-09-21       Impact factor: 53.440

6.  The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development.

Authors:  M Sibilia; A Fleischmann; A Behrens; L Stingl; J Carroll; F M Watt; J Schlessinger; E F Wagner
Journal:  Cell       Date:  2000-07-21       Impact factor: 41.582

7.  Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas.

Authors:  Irene Ischenko; Oleksi Petrenko; Michael J Hayman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

8.  Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma.

Authors:  Janel L Kopp; Guido von Figura; Erin Mayes; Fen-Fen Liu; Claire L Dubois; John P Morris; Fong Cheng Pan; Haruhiko Akiyama; Christopher V E Wright; Kristin Jensen; Matthias Hebrok; Maike Sander
Journal:  Cancer Cell       Date:  2012-11-29       Impact factor: 31.743

9.  The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis.

Authors:  Maximilian Reichert; Shigetsugu Takano; Johannes von Burstin; Sang-Bae Kim; Ju-Seog Lee; Kaori Ihida-Stansbury; Christopher Hahn; Steffen Heeg; Günter Schneider; Andrew D Rhim; Ben Z Stanger; Anil K Rustgi
Journal:  Genes Dev       Date:  2013-01-25       Impact factor: 11.361

10.  Successful growth and characterization of mouse pancreatic ductal cells: functional properties of the Ki-RAS(G12V) oncogene.

Authors:  Franz S Schreiber; Therese B Deramaudt; Thomas B Brunner; Michael I Boretti; Keith J Gooch; Doris A Stoffers; Eric J Bernhard; Anil K Rustgi
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

View more
  22 in total

Review 1.  Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis-A connection to licensing nodes.

Authors:  Christian Schneeweis; Matthias Wirth; Dieter Saur; Maximilian Reichert; Günter Schneider
Journal:  Small GTPases       Date:  2017-01-20

2.  KRAS mutations in the parental tumour accelerate in vitro growth of tumoroids established from colorectal adenocarcinoma.

Authors:  Nabi Mousavi; Sarah Line Bring Truelsen; Grith Hagel; Lars Nannestad Jorgensen; Henrik Harling; Vera Timmermans; Linea Cecilie Melchior; Anna Hammerich Thysen; Steffen Heegaard; Jacob Thastrup
Journal:  Int J Exp Pathol       Date:  2019-03-18       Impact factor: 1.925

Review 3.  Targeting reactive oxygen species in development and progression of pancreatic cancer.

Authors:  Nisha Durand; Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2016-11-23       Impact factor: 4.512

4.  Loss of Wasl improves pancreatic cancer outcome.

Authors:  Ana Hidalgo-Sastre; Judit Desztics; Zahra Dantes; Katharina Schulte; Hilal Kabadayi Ensarioglu; Blessing Bassey-Archibong; Rupert Öllinger; Thomas Engleiter; Lyndsay Rayner; Henrik Einwächter; Juliet M Daniel; Ali Sameer Abdulghani Altaee; Katia Steiger; Marina Lesina; Roland Rad; Maximilian Reichert; Guido von Figura; Jens T Siveke; Roland M Schmid; Clara Lubeseder-Martellato
Journal:  JCI Insight       Date:  2020-05-21

5.  Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer.

Authors:  Yong Li; Yi He; Junya Peng; Zhendong Su; Zeyao Li; Bingjie Zhang; Jing Ma; Meilian Zhuo; Di Zou; Xinde Liu; Xinhong Liu; Wenze Wang; Dan Huang; Mengyue Xu; Jianbin Wang; Haiteng Deng; Jing Xue; Wei Xie; Xun Lan; Mo Chen; Yupei Zhao; Wenming Wu; Charles J David
Journal:  Nat Cancer       Date:  2020-11-02

6.  Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis.

Authors:  Yeon-Sook Choi; Myung Ji Kim; Eun A Choi; Sinae Kim; Eun Ji Lee; Min Ji Park; Mi-Ju Kim; Yeon Wook Kim; Hee-Sung Ahn; Jae Yun Jung; Gayoung Jang; Yongsub Kim; Hyori Kim; Kyunggon Kim; Jin Young Kim; Seung-Mo Hong; Song Cheol Kim; Suhwan Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-18       Impact factor: 12.779

Review 7.  Tissue-specific tumorigenesis: context matters.

Authors:  Günter Schneider; Marc Schmidt-Supprian; Roland Rad; Dieter Saur
Journal:  Nat Rev Cancer       Date:  2017-03-03       Impact factor: 60.716

8.  HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.

Authors:  N Stojanovic; Z Hassan; M Wirth; P Wenzel; M Beyer; C Schäfer; P Brand; A Kroemer; R H Stauber; R M Schmid; A Arlt; A Sellmer; S Mahboobi; R Rad; M Reichert; D Saur; O H Krämer; G Schneider
Journal:  Oncogene       Date:  2016-10-10       Impact factor: 9.867

9.  Critical role of Myc activation in mouse hepatocarcinogenesis induced by the activation of AKT and RAS pathways.

Authors:  B Xin; M Yamamoto; K Fujii; T Ooshio; X Chen; Y Okada; K Watanabe; N Miyokawa; H Furukawa; Y Nishikawa
Journal:  Oncogene       Date:  2017-05-08       Impact factor: 9.867

10.  CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation.

Authors:  Heidi Griesmann; Sebastian Mühl; Jan Riedel; Katharina Theuerkorn; Bence Sipos; Irene Esposito; Gregory B Vanden Heuvel; Patrick Michl
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.